References:
1. Pinter A, et al. J Eur Acad Dermatol Venereol. 2022; doi: 10.1111/jdv.18376. Online ahead of print.
2. Honma M, et al. Dermatol Ther (Heidelb). 2020;10(6):1397–404.
3. Blauvelt A, et al. J Am Acad Dermatol. 2021;85(2):360–8.
4. Armstrong A, et al. Dermatol Ther (Heidelb). 2020;10(1):133–50.
5. Taltz, Summary of Product Characteristics, May 2022.

^aResults from the primary endpoint are not presented¹; ^bData presented from subgroup of patients who received the EMA approved on-label dosing; unadjusted CIs were calculated using the normal approximation; for missing data, the outcomes of interest were imputed using NRI1; ^cUnadjusted, actual response rates of the primary outcome at Week 12 for the individual drugs; FMA ORs (95% CIs) for sPGA (0, 1) and/or PASI90 were reported as 1.7 (0.9, 2.7) for Taltz vs. brodalumab, 1.7 (1.2, 2.3) for Taltz vs. secukinumab, 1.7 (1.1, 2.2) for Taltz vs. risankizumab, 2.3 (1.5, 3.9) for Taltz vs. tildrakizumab, 2.1 (1.6, 2.8) for Taltz vs. guselkumab, 2.7 (1.7, 3.3) for Taltz vs. adalimumab, and 3.2 (2.0, 4.5) for Taltz vs. ustekinumab; FMA results are not shown here¹; ^dUnadjusted, actual response rates of PASI100 responses at Week 12 for the individual drugs; FMA ORs (95% CIs) for PASI100 were reported as 1.0 (0.6, 1.8) for Taltz vs. brodalumab, 1.5 (1.1, 2.2) for Taltz vs. secukinumab, 1.6 (1.2, 2.2) for Taltz vs. risankizumab, 2.1 (1.5, 2.7) for Taltz vs. guselkumab, 2.3 (1.4, 3.9) for Taltz vs. tildrakizumab, 3.8 (2.5, 5.9) for Taltz vs. adalimumab, and 4.8 (2.7, 9.1) for Taltz vs. ustekinumab; FMA results are not shown here¹; ^eUNCOVER-J was a Phase 3, multicentre, single-arm, open-label study of Taltz for the treatment of patients with moderate to severe psoriasis in Japan (N=91)²; ^fUNCOVER-3 was a Phase 3, randomised, double-blinded, multicentre study in patients with moderate to severe plaque psoriasis³; ^gPASI response rates over time through 264 weeks with the approved Taltz dosing regimen: starting dose of 160 mg, then Taltz 80 mg Q2W up to and including Week 12, followed by Taltz 80 mg Q4W thereafter. Note: Data collected at visits with dose adjustment (Taltz Q2W after Week 60 at investigator’s discretion) were excluded before imputations were applied. Data presented for the as observed method of efficacy analysis, where percentages are calculated by using the number of patients with non-missing data at Weeks 60, 108, 156, 204, and 264 as the denominator. ^3,5

Abbreviations:
CI, confidence interval; EMA, European Medicines Agency; FMA, Frequentist Model Averaging; IL, interleukin; NRI, non-responder imputation; OR, odds ratio; PASI, Psoriasis Area and Severity Index; PASI90, ≥90% improvement from baseline in PASI; PASI100, 100% improvement from baseline in PASI; PSoHO, Psoriasis Study of Health Outcomes; Q2W, once every 2 weeks; Q4W, once every 4 weeks; sPGA, static Physician’s Global Assessment.

This site is intended for Israeli Healthcare Professionals only.
The content of this site may be promotional in nature.

Copyright | Privacy policy | Accessibility Statement | Terms of use
© 2024 Eli Lilly Israel. All rights reserved.
PP-IX-IL-0865